| Eisai enters into partnership with Quintiles | Posted on 02/11/2009 in Pharmaceutical Company Product News Eisai and fellow pharmaceutical firm Quintiles have signed an agreement to jointly develop six anti-cancer drugs in its oncology pipeline in order to accelerate its product creation strategy for the oncology-related disease area.
The firms will share clinical development risks and collaborate to increase the speed and success in developing the compounds, which include eribulin mesylate (E7389), E7080, Ontak (denileukin diftitox), E7820, E6201 and E7050.
As part of the agreement, Quintiles will conduct proof-of-concept studies for 11 tumour indications, while Eisai will continue ongoing development for 18 other indications for the same six products.
Through the agreement, Eisai aims to reduce development time by working on candidate compounds for multiple indications simultaneously.
Another firm Eisai has collaborated with in recent times is Takeda. They announced last month that they had jointly submitted an application for the use of proton pump inhibitors with concomitant therapy for the treatment of helicobacter pylori.
Other news stories from 02/11/2009
Read more in the Zenopa News Archive
How this news is generated
|  |
|
